A phase I clinical study of BBI608 in adult patient with advanced solid tumours.
The primary objective of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of BBBI608 given orally daily and continuously.
See Trial Summary.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society
